DESCRIPTION OF BUSINESS - License and Distribution Agreements (BioInvent International AB) (Details) kr / shares in Units, $ in Thousands, kr in Millions |
1 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
|
Nov. 30, 2020
USD ($)
|
Oct. 31, 2020
SEK (kr)
kr / shares
shares
|
Dec. 31, 2025
USD ($)
|
Dec. 31, 2024
USD ($)
|
Dec. 31, 2020
USD ($)
|
|
| Description of Business and Basis of Presentation | |||||
| Proceeds from sale of ordinary shares | $ 5,878 | $ 15,000 | |||
| BioInvent International AB | |||||
| Description of Business and Basis of Presentation | |||||
| Upfront payment | $ 5,900 | ||||
| Acquired in-process research and development | $ 5,900 | ||||
| Number of new shares issued | shares | 1,200,000 | ||||
| Number of warrants issued | shares | 588,000 | ||||
| Each warrants issued for new share | shares | 1 | ||||
| Subscription period for warrants (in years) | 5 years | ||||
| Offering price per share | kr / shares | kr 78.5 | ||||
| Investment | kr | kr 53.8 | ||||
| BioInvent International AB | Maximum | |||||
| Description of Business and Basis of Presentation | |||||
| Potential milestones and royalties | $ 83,000 | ||||
| X | ||||||||||
- Definition n/a. No definition available.
|
| X | ||||||||||
- Definition Number of shares invested under equity method investment. No definition available.
|
| X | ||||||||||
- Definition The potential milestone and royalty payment. No definition available.
|
| X | ||||||||||
- Definition The amounts of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. No definition available.
|
| X | ||||||||||
- Definition Period for subscription of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition The amount of upfront payment. No definition available.
|
| X | ||||||||||
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. No definition available.
|
| X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks of a company. No definition available.
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|